Key statistics
As of last trade Neurocrine Biosciences Inc (0K6R:LSE) traded at 125.25, -22.23% below its 52-week high of 161.05, set on Dec 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 125.25 |
| Low | 125.25 |
| Bid | -- |
| Offer | -- |
| Previous close | 125.25 |
| Average volume | 5.64k |
|---|---|
| Shares outstanding | 100.36m |
| Free float | 98.88m |
| P/E (TTM) | 26.62 |
| Market cap | 12.46bn USD |
| EPS (TTM) | 4.66 USD |
Data delayed at least 20 minutes, as of Feb 13 2026 18:16 GMT.
More ▼
Press releases
- Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
- Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
- Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
- Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
- Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
- Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
- Neurocrine Biosciences to Host R&D Day on December 16
- Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
More ▼
